关于 2023 年半年度相关事项的独立意见 宁波戴维医疗器械股份有限公司独立董事 （此页以下无正文） （此页无正文，为《宁波戴维医疗器械股份有限公司独立董事关 于 2023 年半年度相关事项的独立意见》之签字页） 独立董事： 根据《深圳证券交易所创业板股票上市规则》、《深圳证券 交易所上市公司自律监管指引第2号——创业板上市公司规范运 作》、《关于在上市公司建立独立董事制度的指导意见》以及《公 司章程》、《独立董事工作制度》等有关规定，作为公司的独立 董事，本着对公司、全体股东和投资者负责的态度，基于实事求 是和独立判断的立场，对报告期内公司控股股东及关联方占用公 司资金情况、对外担保情况、关联交易情况进行了认真的核查， 现发表如下独立意见： 一、关于控股股东及其他关联方占用公司资金、公司对外 担保情况的独立意见 经核查，发表独立意见如下： 1、报告期内，公司不存在与控股股东及其他关联方发生经营 性或非经营性资金往来的情形，不存在公司控股股东或其他关联 方占用公司资金的情形。 2、报告期内，公司未发生任何形式的对外担保事项，亦不存 在以前年度发生并累积至2023年06月30日的对外担保情形。 二、关于公司关联 ...

证券代码：300314 证券简称：戴维医疗 公告编号：2023-029 | 序号 | 产品名称 | 注册分类 | 临床用途 | | --- | --- | --- | --- | | | | | 适用于各期内痔及混合 | | 1 | 一次性使用肛肠套扎器 | II 类 | 痔或直肠良性息肉的套 | | | | | 扎治疗。 | 一次性使用肛肠套扎器通过负压将痔上黏膜病灶处吸入套扎管 内，释放套扎圈或弹力线进行套扎，以此来阻断供应痔的动脉、静脉， 防止静脉回流，使痔块发生坏死脱落形成瘢痕，起到直接去除病灶的 效果。相对于传统手术消除了伤口感染和止血困难造成的手术风险， 同时在实际临床使用时能极大地简化手术流程，便于术者使用，其带 来的社会和经济效益十分明显，具有广阔的临床应用前景。 上述医疗器械产品目前所处的审批阶段为注册申请受理，后续所 需的审批流程为技术审评、行政审批、制证。上述品种注册申请受理 对公司近期业绩不会产生影响，审评工作在各阶段所需的时间和结果 均具有一定的不确定性，公司将对上述品种的后续进展情况及时履行 信息披露义务。敬请广大投资者予以关注并注意投资风险。 宁波戴维医疗器械股份有限公司 特此公 ...

证券代码：300314 证券简称：戴维医疗 宁波戴维医疗器械股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------------|---------------|----------------| | | | 编号：20230607 | | 投资者关系活动 | ☑特定对象调研 | □分析师会议 | | 类别 | □媒体采访 | □业绩说明会 | □新闻发布会 □路演活动 ☑现场参观 □其他 （电话会议） 参与单位名称及 开源证券、交银基金、财通基金、东方红基金、华泰柏瑞基金、 人员姓名 睿扬基金、凯丰投资、煜德投资、富国基金、博道基金、广发 资管、凯丰投资、山楂树资产、Dymon、诺德基金、天风证券、 博时基金、汐泰投资、永赢基金、兴业基金、红筹投资、和谐 汇一、谢诺投资、东吴资管、慎知资产、湘财基金、汇森投资、 五地基金、崇山投资、南土资产、OrbiMed 时间 2023 年 06 月 06 日、06 月 07 日 地点 子公司维尔凯迪二楼会议室 上市公司接待人 董事会秘书、财务总监：李则东；维尔凯迪销售总监：薛浩宇； 员姓名 证券事务代表：陈志昂；证券事务助理：郑亚 ...

Financial Performance - The company's revenue for Q1 2023 was ¥157,862,759.12, representing a 61.55% increase compared to ¥97,715,502.09 in the same period last year[5] - Net profit attributable to shareholders reached ¥50,019,287.49, a significant increase of 421.75% from ¥9,586,811.39 in the previous year[5] - Basic earnings per share rose to ¥0.1737, up 421.62% from ¥0.0333 in the previous year[5] - Total operating revenue for Q1 2023 reached ¥157,862,759.12, a significant increase of 61.6% compared to ¥97,715,502.09 in the same period last year[22] - Net profit for Q1 2023 was ¥50,019,287.49, compared to ¥9,586,811.39 in Q1 2022, reflecting a growth of 421.5%[23] - The total comprehensive income for the first quarter of 2023 was CNY 50,019,287.49, compared to CNY 9,586,811.39 in the same period last year, representing a significant increase[24] - Basic and diluted earnings per share for the first quarter were both CNY 0.1737, up from CNY 0.0333 year-over-year[24] Cash Flow - The net cash flow from operating activities improved to ¥6,903,274.52, compared to a negative cash flow of ¥17,914,205.73 in the same quarter last year, marking a 138.54% increase[5] - Cash inflow from operating activities was CNY 164,362,355.66, an increase from CNY 113,866,702.84 in the previous year[25] - The net cash flow from operating activities was CNY 6,903,274.52, a turnaround from a negative CNY 17,914,205.73 in the same period last year[25] - The net cash flow from investing activities was CNY 15,754,710.15, down from CNY 52,502,957.04 year-over-year[27] - The company reported a cash outflow of CNY 340,000,000.00 related to investment activities, compared to CNY 300,000,000.00 in the previous year[27] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,282,938,126.23, a 2.41% increase from ¥1,252,694,543.64 at the end of the previous year[5] - Total liabilities decreased to ¥173,810,887.79 from ¥193,390,231.36, a reduction of 10.1%[20] - The total current assets increased to ¥956,546,111.80 from ¥922,874,746.07, showing a growth of approximately 3.7%[18] - The total equity attributable to shareholders increased to ¥1,109,127,238.44 from ¥1,059,304,312.28, reflecting a growth of 4.7%[20] Shareholder Information - The total number of common shareholders at the end of the reporting period is 15,821[12] - The top three shareholders hold significant stakes: Chen Zaihong (24.69%, 71,108,200 shares), Chen Yunqin (21.12%, 60,820,000 shares), and Chen Zaiwei (20.25%, 58,320,000 shares)[12] - The top ten shareholders include various investment funds, with the largest being a mix of individual and institutional investors[12] - The company has a total of 98,645,352 shares under lock-up agreements, primarily due to executive lock-up policies[16] Operational Highlights - The company reported a significant increase in accounts receivable, which rose by 78.41% to ¥30,397,727.36, attributed to increased credit limits for distributors[9] - The company experienced a 106.03% increase in prepayments, totaling ¥16,711,821.99, due to higher advance payments for materials and testing fees[9] - Research and development expenses for Q1 2023 were ¥8,627,320.97, an increase of 11.7% from ¥7,723,486.29 in the previous year[22] - The company plans to continue its market expansion and product development strategies in the upcoming quarters[12] - The company plans to continue expanding its market presence and investing in new product development to drive future growth[20] Investment Income - Investment income for the quarter was ¥6,596,225.75, a recovery from a loss of ¥12,519,228.93 in the same period last year[9] - The company reported an investment income of ¥6,596,225.75, recovering from a loss of ¥12,519,228.93 in the same quarter last year[23] Inventory and Cash Equivalents - Inventory at the end of Q1 2023 was ¥154,769,528.07, up from ¥148,267,523.40 at the beginning of the year, reflecting a growth of about 4.3%[18] - The company's cash and cash equivalents at the end of Q1 2023 amounted to ¥410,519,510.89, an increase from ¥390,938,480.54 at the beginning of the year[18] - The cash and cash equivalents at the end of the period amounted to CNY 409,457,239.69, an increase from CNY 369,011,171.40 at the end of the previous year[27] Other Information - The company has no preferred shareholders as of the reporting period[12] - The first quarter report was not audited[28]

| 投资者关系活动 | □特定对象调研 □分析师会议 | | --- | --- | | 类别 | □媒体采访 ■业绩说明会 | | | □新闻发布会 □路演活动 | | | □现场参观 | | | □其他 （电话会议） | | 参与单位名称及 | 通过全景网"投资者关系互动平台"（https://ir.p5w.net） | | 人员姓名 | 参与本次年度业绩说明会的广大投资者 | | 时间 | 2023 年 04 月 10 日 15:00 – 17:00 | | 地点 | 全景网"投资者关系互动平台"（https://ir.p5w.net） | | 上市公司接待人 | 董事长、总经理陈再宏先生 | | 员姓名 | 财务总监、董事会秘书李则东先生 | | | 独立董事陈赛芳女士 | | | 公司于 2023 年 04 月 10 日（星期一）15:00-17:00 在全 | | | 景网举办 2022 年度业绩说明会，本次年度业绩说明会采用网 | | | 络远程的方式举行。业绩说明会问答环节内容如下： | | | 1、一季报有没有预增公告？ | | | 您好！根据创业板上市公司相关规则，创业板上市公司季 | | ...

Financial Performance - The company reported that all board members attended the meeting to review the annual report [3]. - The company’s operating revenue for 2022 was ¥506,036,692.34, representing a 6.73% increase compared to ¥474,132,641.45 in 2021 [25]. - The net profit attributable to shareholders for 2022 was ¥97,577,629.13, a 21.66% increase from ¥80,206,691.31 in 2021 [25]. - The net cash flow from operating activities increased by 116.72% to ¥111,569,973.76 in 2022, up from ¥51,480,031.08 in 2021 [25]. - The basic earnings per share for 2022 was ¥0.34, a 21.43% increase from ¥0.28 in 2021 [25]. - Total assets at the end of 2022 were ¥1,252,694,543.64, an 8.38% increase from ¥1,155,886,846.70 at the end of 2021 [25]. - The company achieved a total revenue of 506.04 million yuan, representing a year-on-year growth of 6.73% [47]. - The net profit attributable to shareholders was 97.58 million yuan, an increase of 21.66% compared to the previous year [47]. - The company reported a gross margin of 45%, indicating strong profitability [68]. - The company reported a total revenue of 1.2 billion RMB for the fiscal year 2022, representing a year-over-year growth of 15% [149]. Dividends and Shareholder Returns - The company plans to distribute a cash dividend of 1.50 RMB per 10 shares to all shareholders, based on a total of 288,000,000 shares [3]. - The total distributable profit for the year was RMB 482,687,015.68, with cash dividends accounting for 100% of the profit distribution [170]. - The cash dividend distribution plan is subject to approval at the annual general meeting, reflecting the company's commitment to shareholder returns [170]. Research and Development - The company invested 45.869 million yuan in R&D, which accounted for 9.06% of its total revenue, supporting innovation and product structure optimization [59]. - The company is focusing on product development and market expansion, particularly in emergency equipment and medical consumables [46]. - The company is actively pursuing new product registrations, including a new type of neonatal jaundice treatment blanket and a heated respiratory tube system [70]. - The company is developing new electric surgical instruments, including a linear cutting stapler with a maximum rotation angle of 60°, aimed at enhancing operational convenience and precision [84]. - The company is enhancing its product offerings with integrated monitoring functions for vital signs in neonatal care devices [66]. Market Expansion and Strategy - The company has established a network of over 40 international agents, selling products to over 100 countries across Asia, Africa, Europe, and South America [50]. - The company plans to expand its market presence internationally, focusing on increasing overseas sales channels [73]. - The company aims to enhance its market presence through the development of innovative medical devices, which may lead to increased revenue streams in the coming years [28]. - The company plans to expand its market presence in Southeast Asia, targeting a 20% increase in market share by 2025 [140]. - The company is exploring potential acquisitions to strengthen its market position, with a budget of $50 million allocated for this purpose [68]. Product Development and Innovation - The company is advancing its product technology, with some products reaching the third generation and others in development approaching the fourth generation level [36]. - The company has launched the first domestic third-generation electric cutting stapler, challenging dominant imported brands and gradually closing the gap [40]. - The company is expanding its product line with new technologies aimed at improving neonatal care, including radiation warmers and transport incubators [64]. - The company has introduced several new infant incubators, including models YP-100 and YP-100A, which are classified as Class III medical devices and are effective until February 17, 2024 [64]. - The company is developing a new emergency rescue integrated machine that combines monitoring, respiratory, and defibrillation functions, addressing the complexity and size issues of existing devices [83]. Governance and Compliance - The company strictly adheres to corporate governance regulations, ensuring equal rights for all shareholders and maintaining transparency in operations [132]. - The board of directors consists of 9 members, including 3 independent directors, complying with legal requirements [133]. - The company has established specialized committees within the board, including a strategic committee and an audit committee, to enhance decision-making [133]. - The company has implemented a robust internal management and control system to improve governance standards [132]. - The company is committed to adhering to regulatory requirements and improving its governance practices [158]. Social Responsibility and Sustainability - The company actively participated in social responsibility initiatives, donating 276,100 yuan in 2022 [181]. - The company is committed to sustainability initiatives, aiming for a 30% reduction in carbon emissions by 2025 [140]. - The company emphasizes employee rights protection and has established a comprehensive performance evaluation system [179]. - The company adheres to environmental protection laws and has not been penalized for violations [178]. Risks and Challenges - The company faces risks from industry regulation, market competition, and technology, and will enhance R&D efforts to mitigate these risks [123]. - The company is addressing the risk of declining newborn birth rates by expanding its product offerings in infant care and emergency respiratory treatment [125]. - The company anticipates potential price declines due to centralized procurement policies for high-value medical consumables and will adapt its bidding strategies accordingly [125]. - The company will monitor raw material price fluctuations and implement flexible procurement strategies to manage costs effectively [126].

宁波戴维医疗器械股份有限公司（以下简称"公司"）《2022年年度 报告全文》及《2022年年度报告摘要》已于2023年03月31日在中国证监会 指定信息披露网站巨潮资讯网（http://www.cninfo.com.cn）披露。为了 让广大投资者进一步了解公司2022年度经营情况，公司将于2023年04月10 日（星期一）下午15:00至17:00在全景网举办2022年度业绩说明会，本次 年度业绩说明会将采用网络远程的方式举行，投资者可登录全景网"投资 者关系互动平台"（https://ir.p5w.net）参与本次年度业绩说明会。 出席本次年度业绩说明会的人员有：公司董事长兼总经理陈再宏先生， 财务总监兼董事会秘书李则东先生，独立董事陈赛芳女士。 证券代码：300314 证券简称：戴维医疗 公告编号：2023-016 宁波戴维医疗器械股份有限公司 关于举行2022年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 欢迎广大投资者积极参与本次网上说明会。 特此公告。 宁波戴维医疗器械股份有限公司 董事会 2023 年 03 月 31 日 ...